DeWITT, N.Y. — Velocity Clinical Research Syracuse on Wednesday formally opened a new location at 5000 Brittonfield Parkway in DeWitt.
Velocity Clinical Research Syracuse — formerly Clarity Clinical Research — is a DeWitt–based clinical research company that conducts clinical trials for a variety of therapeutic areas.
Durham, North Carolina–based Velocity Clinical Research completed the acquisition of the local company at the end of 2021, per a June 23 announcement.
Clarity Clinical Research LLC previously operated at 6700 Kirkville Road in DeWitt.
Since joining Velocity, the local Syracuse clinic has doubled the number of staff and tripled the number of active clinical trials for Central New Yorkers, resulting in the need for a new larger facility. Velocity Syracuse currently has just over 20 employees with opening for three more, per a company spokesperson.
The new larger clinic was designed specifically to accommodate the company’s growing number of clinical trial volunteers and staff.
Clinical trials at this new location now include research on diabetes; chronic obstructive pulmonary disease, or COPD; along with vaccines for flu, Lyme disease, and respiratory syncytial virus (RSV). The company has also expanded its therapeutic areas to offer nonalcoholic steatohepatitis and memory studies, including trials for the prevention of Alzheimer’s disease.
“What I really love about this work is getting to know our trial participants. We see them frequently over the course of a study, and they and their families become part of our Velocity family during that time,” Kristen Stebbins, site manager at Velocity Clinical Research Syracuse, said “The hope that I see in the eyes of trial participants and their caregivers is the reason I do this.”
Clarity Clinical Research was founded in Syracuse in 2017 with a focus on Alzheimer’s disease clinical trials. In 2021, Clarity Clinical Research merged with Velocity Clinical Research, an international integrated clinical site business with over 30 locations across the U.S. and Europe.